Studying the Potential of Upregulated Ptgs2 and Vegf-C Besides Hyper-Methylation of Ptgs2 Promoter As Biomarkers of Acute Myeloid Leukemia Publisher Pubmed



Kianizadeh M¹ ; Rezvany MR^{1, 2, 3} ; Namjoo S^{1, 4} ; Barati M⁵ ; Mohammadi MH⁶ ; Ghasemi B¹ ; Tabatabaei T¹ ; Ghavamzadeh A⁷ ; Zaker F^{1, 8, 9} ; Teimooritoolabi L⁴
Source: Molecular Biology Reports Published:2022

Abstract

Hereby, we aimed to investigate the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) and Vascular Endothelial Factor-C (VEGF-C) besides the methylation of PTGS2 in AML patients. VEGF-C and PTGS2 expression analysis were evaluated in newly diagnosed AML patients and healthy controls by quantitative Reverse Transcriptase PCR method. Also, PTGS2 methylation status was evaluated by Methylation-Sensitive High-Resolution Melting Curve Analysis (MS-HRM). While 34% of patients were female, the mean age of the patients was 43.41 ± 17.60 years suffering mostly from M4 (48.21%) type of AML. Although methylation level between patients and controls was not significantly different, none of the normal controls showed methylation in the PTGS2 promoter. PTGS2 and VEGF-C levels were elevated in AML cases and correlated with WBC, Platelet, and Hemoglobin levels. The survival of patients with overexpressed VEGF-C and PTGS2 was poorer than others. It can be concluded that PTGS2 and especially VEGF-C expression but not PTGS2 methylation can be considered as diagnostic biomarkers for AML. © 2022, The Author(s), under exclusive licence to Springer Nature B.V.